Ocular adverse drug reactions

F. W. Fraunfelder

doi:10.1517/14740338.2.4.411

Ocular adverse drug reactions

F. W. Fraunfelder

Research output: Contribution to journal › Review article › peer-review

13 Scopus citations

Abstract

Drug-induced ocular side effects are described according to recent reports from the literature, the National Registry of Drug-Induced Ocular Side Effects, the World Health Organization (WHO) and the FDA. Adverse events are categorised as certain, probable/likely, possible, unlikely, conditional/unclassified and unassessable/unclassifiable where indicated. Ocular side effects of clinical importance are highlighted with guidelines for recognition, reporting and treatment of adverse drug reactions (ADRs). The current and future status of pharmacovigilance in ocular toxicology is addressed.

Original language	English (US)
Pages (from-to)	411-420
Number of pages	10
Journal	Expert Opinion on Drug Safety
Volume	2
Issue number	4
DOIs	https://doi.org/10.1517/14740338.2.4.411
State	Published - Jul 1 2003
Externally published	Yes

Keywords

adverse drug reactions (ADRs)
ocular side effects
ocular toxicology
pharmacovigilance

ASJC Scopus subject areas

Pharmacology (medical)

Access to Document

10.1517/14740338.2.4.411

Cite this

@article{eb6b8498b2304d3c93c4ffca7229793a,

title = "Ocular adverse drug reactions",

abstract = "Drug-induced ocular side effects are described according to recent reports from the literature, the National Registry of Drug-Induced Ocular Side Effects, the World Health Organization (WHO) and the FDA. Adverse events are categorised as certain, probable/likely, possible, unlikely, conditional/unclassified and unassessable/unclassifiable where indicated. Ocular side effects of clinical importance are highlighted with guidelines for recognition, reporting and treatment of adverse drug reactions (ADRs). The current and future status of pharmacovigilance in ocular toxicology is addressed.",

keywords = "adverse drug reactions (ADRs), ocular side effects, ocular toxicology, pharmacovigilance",

author = "Fraunfelder, {F. W.}",

note = "Funding Information: The author is indebted to the national centres mentioned in this study that contributed data. The opinions and conclusions, however, are not necessarily those of either the various centres or of the WHO. The author has no proprietary interest in these materials. This study was supported in part by an unrestricted grant from Research to Prevent Blindness.",

year = "2003",

month = jul,

day = "1",

doi = "10.1517/14740338.2.4.411",

language = "English (US)",

volume = "2",

pages = "411--420",

journal = "Expert Opinion on Drug Safety",

issn = "1474-0338",

publisher = "Informa Healthcare",

number = "4",

}

TY - JOUR

T1 - Ocular adverse drug reactions

AU - Fraunfelder, F. W.

N1 - Funding Information: The author is indebted to the national centres mentioned in this study that contributed data. The opinions and conclusions, however, are not necessarily those of either the various centres or of the WHO. The author has no proprietary interest in these materials. This study was supported in part by an unrestricted grant from Research to Prevent Blindness.

PY - 2003/7/1

Y1 - 2003/7/1

N2 - Drug-induced ocular side effects are described according to recent reports from the literature, the National Registry of Drug-Induced Ocular Side Effects, the World Health Organization (WHO) and the FDA. Adverse events are categorised as certain, probable/likely, possible, unlikely, conditional/unclassified and unassessable/unclassifiable where indicated. Ocular side effects of clinical importance are highlighted with guidelines for recognition, reporting and treatment of adverse drug reactions (ADRs). The current and future status of pharmacovigilance in ocular toxicology is addressed.

AB - Drug-induced ocular side effects are described according to recent reports from the literature, the National Registry of Drug-Induced Ocular Side Effects, the World Health Organization (WHO) and the FDA. Adverse events are categorised as certain, probable/likely, possible, unlikely, conditional/unclassified and unassessable/unclassifiable where indicated. Ocular side effects of clinical importance are highlighted with guidelines for recognition, reporting and treatment of adverse drug reactions (ADRs). The current and future status of pharmacovigilance in ocular toxicology is addressed.

KW - adverse drug reactions (ADRs)

KW - ocular side effects

KW - ocular toxicology

KW - pharmacovigilance

UR - http://www.scopus.com/inward/record.url?scp=0141818235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141818235&partnerID=8YFLogxK

U2 - 10.1517/14740338.2.4.411

DO - 10.1517/14740338.2.4.411

M3 - Review article

C2 - 12904097

AN - SCOPUS:0141818235

SN - 1474-0338

VL - 2

SP - 411

EP - 420

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

IS - 4

ER -

Ocular adverse drug reactions

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this